We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sanofi Sa | LSE:0A2V | London | Ordinary Share | SANOFI ADR REP 1 1/2 ORD (CDI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 328 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Health & Allied Services,nec | 43.07B | 5.4B | 4.2694 | 21.38 | 0 |
TIDM0A2V
RNS Number : 9505I
Societe Generale SA
06 April 2020
Date: 06/04/2020
Not for the distribution, directly or indirectly in to the United States or any jurisdiction in which such distribution would be unlawful.
SANOFI - Stabilisation Notice
Societe Generale (Contact: RONAN MURPHY; telephone: +44-20-7676-7463) hereby gives notice that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Regulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC).ty
The Securities: ============================================ ============================================ Issuer: SANOFI ============================================ ============================================ Guarantor (if any): n/a ============================================ ============================================ Aggregate Nominal Amount: EUR 250m, EUR 250m ============================================ ============================================ Description: Maturity: 1(st) April 2025, 1(st) April 2030 ============================================ ============================================ Offer price: 102.427, 106.539 ============================================ ============================================ Stabilisation: ============================================ ============================================ Stabilising managers: SG CIB ============================================ ============================================ Stabilisation Period expected 06/04/2020 to start on: ============================================ ============================================ Stabilisation period expected 08/05/2020 to end no later than: ============================================ ============================================ Existence, maximum size The Stabilising Manager(s) and conditions of use of may over-allot the securities over-allotment facility: to the extent permitted in accordance with SG's Policy. ============================================ ============================================
In connection with the offer of the above securities, the Stabilising Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilising Manager(s) will take any Stabilising action and any Stabilising action, if begun, may be ended at any time. Any Stabilising action or over-allotment shall be conducted in accordance with all applicable laws and rules.
This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.
This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.
In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.
This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
STAUPUCCCUPUGCQ
(END) Dow Jones Newswires
April 06, 2020 10:46 ET (14:46 GMT)
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions